Altimmune Statistics
Total Valuation
Altimmune has a market cap or net worth of $642.44 million. The enterprise value is $461.97 million.
Important Dates
The next estimated earnings date is Thursday, February 26, 2026, before market open.
| Earnings Date | Feb 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Altimmune has 125.23 million shares outstanding. The number of shares has increased by 17.16% in one year.
| Current Share Class | 125.23M |
| Shares Outstanding | 125.23M |
| Shares Change (YoY) | +17.16% |
| Shares Change (QoQ) | +9.75% |
| Owned by Insiders (%) | 0.69% |
| Owned by Institutions (%) | 36.00% |
| Float | 124.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32,841.97 |
| Forward PS | 175,292.71 |
| PB Ratio | 2.82 |
| P/TBV Ratio | 3.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23,098.42 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.18, with a Debt / Equity ratio of 0.09.
| Current Ratio | 17.18 |
| Quick Ratio | 16.83 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -118.87 |
Financial Efficiency
Return on equity (ROE) is -52.61% and return on invested capital (ROIC) is -33.59%.
| Return on Equity (ROE) | -52.61% |
| Return on Assets (ROA) | -30.87% |
| Return on Invested Capital (ROIC) | -33.59% |
| Return on Capital Employed (ROCE) | -43.95% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | $339 |
| Profits Per Employee | -$1.42M |
| Employee Count | 59 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -681,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.62% in the last 52 weeks. The beta is 0.03, so Altimmune's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | -17.62% |
| 50-Day Moving Average | 4.73 |
| 200-Day Moving Average | 4.56 |
| Relative Strength Index (RSI) | 59.62 |
| Average Volume (20 Days) | 5,550,474 |
Short Selling Information
The latest short interest is 26.41 million, so 21.09% of the outstanding shares have been sold short.
| Short Interest | 26.41M |
| Short Previous Month | 25.81M |
| Short % of Shares Out | 21.09% |
| Short % of Float | 21.23% |
| Short Ratio (days to cover) | 4.52 |
Income Statement
In the last 12 months, Altimmune had revenue of $20,000 and -$83.92 million in losses. Loss per share was -$1.06.
| Revenue | 20,000 |
| Gross Profit | -67.78M |
| Operating Income | -90.46M |
| Pretax Income | -84.60M |
| Net Income | -83.92M |
| EBITDA | -90.34M |
| EBIT | -90.46M |
| Loss Per Share | -$1.06 |
Full Income StatementBalance Sheet
The company has $210.78 million in cash and $15.91 million in debt, with a net cash position of $194.87 million or $1.56 per share.
| Cash & Cash Equivalents | 210.78M |
| Total Debt | 15.91M |
| Net Cash | 194.87M |
| Net Cash Per Share | $1.56 |
| Equity (Book Value) | 185.60M |
| Book Value Per Share | 1.94 |
| Working Capital | 204.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$66.35 million and capital expenditures -$10,000, giving a free cash flow of -$66.36 million.
| Operating Cash Flow | -66.35M |
| Capital Expenditures | -10,000 |
| Free Cash Flow | -66.36M |
| FCF Per Share | -$0.53 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -452,310.00% |
| Pretax Margin | -422,980.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Altimmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.16% |
| Shareholder Yield | -17.16% |
| Earnings Yield | -12.78% |
| FCF Yield | -10.10% |
Analyst Forecast
The average price target for Altimmune is $16.00, which is 211.89% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.00 |
| Price Target Difference | 211.89% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | 477.52% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Altimmune has an Altman Z-Score of 3.82 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.82 |
| Piotroski F-Score | 2 |
